A1ZN34:BVMF
Astrazeneca Plc Bdr
139,90 R$
0,00%
(0,00) 1 d.
16. okt., 17:06:00 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: A1ZN34…
Atvērt
143,33 R$
Augsta
143,33 R$
Zema
138,81 R$
Tirgus kapitalizācija
259,42 mljrd.
Vid. apjoms
892,00
Apjoms
1,25 tūkst.
Augstākā 52 ned.
190,40 R$
Zemākā 52 ned.
129,06 R$
Apgrozībā esošās akcijas
1,55 mljrd.
Darbinieku skaits
96 tūkst.
Atvērt
143,33 R$
Augsta
143,33 R$
Zema
138,81 R$
Tirgus kapitalizācija
259,42 mljrd.
Vid. apjoms
892,00
Apjoms
1,25 tūkst.
Augstākā 52 ned.
190,40 R$
Zemākā 52 ned.
129,06 R$
Apgrozībā esošās akcijas
1,55 mljrd.
Darbinieku skaits
96 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Yahoo Finance
·
pirms 21 stundas
Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus
Insider Monkey
·
pirms 1 dienas
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?
Traders Union
·
pirms 1 dienas
AstraZeneca shares technical analysis: Upward price move confirms strong near-term momentum
The Twelfth Magpie
·
pirms 1 dienas
While the market panics about the FTSE 100, Citi just raised its AstraZeneca target to £186
Profils
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Par “Astrazeneca Plc Bdr”
ĢenerāldirektorsPascal Soriot
Darbinieki96,1 tūkst.
Dibināšanas datums1999. gada 6. apr.
Galvenais birojsKembridža, Kembridžšīra, Apvienotā Karaliste
Sektors-
Tīmekļa vietneastrazeneca.com